10x Genomics, Inc. (NASDAQ:TXG) Receives $62.40 Consensus PT from Brokerages

10x Genomics, Inc. (NASDAQ:TXGGet Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $62.40.

A number of research firms have weighed in on TXG. Bank of America upgraded 10x Genomics from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $36.00 to $54.00 in a research report on Tuesday, December 12th. Wolfe Research began coverage on 10x Genomics in a research report on Wednesday, December 13th. They issued an “outperform” rating and a $55.00 target price for the company. Barclays upped their target price on 10x Genomics from $45.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, January 25th. Finally, Guggenheim initiated coverage on 10x Genomics in a research report on Thursday, December 14th. They set a “buy” rating and a $60.00 price objective for the company.

Read Our Latest Analysis on 10x Genomics

10x Genomics Stock Down 0.9 %

Shares of 10x Genomics stock opened at $49.11 on Friday. The firm has a market cap of $5.81 billion, a P/E ratio of -25.71 and a beta of 1.92. The business has a 50-day moving average price of $48.96 and a 200 day moving average price of $46.24. 10x Genomics has a fifty-two week low of $33.79 and a fifty-two week high of $63.57.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider James Wilbur sold 14,718 shares of the business’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $42.09, for a total transaction of $619,480.62. Following the sale, the insider now directly owns 86,806 shares of the company’s stock, valued at approximately $3,653,664.54. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Serge Saxonov sold 3,757 shares of the company’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $43.34, for a total value of $162,828.38. Following the transaction, the chief executive officer now directly owns 851,169 shares of the company’s stock, valued at $36,889,664.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James Wilbur sold 14,718 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $42.09, for a total transaction of $619,480.62. Following the completion of the sale, the insider now owns 86,806 shares of the company’s stock, valued at $3,653,664.54. The disclosure for this sale can be found here. Insiders have sold a total of 33,341 shares of company stock valued at $1,458,996 in the last three months. 10.65% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On 10x Genomics

Several hedge funds have recently made changes to their positions in TXG. Indiana Trust & Investment Management CO acquired a new stake in shares of 10x Genomics during the third quarter worth approximately $29,000. Atlas Capital Advisors LLC grew its holdings in shares of 10x Genomics by 41.7% in the 2nd quarter. Atlas Capital Advisors LLC now owns 935 shares of the company’s stock valued at $42,000 after buying an additional 275 shares during the period. UMB Bank n.a. boosted its stake in 10x Genomics by 51.6% in the 4th quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after purchasing an additional 266 shares during the period. Comerica Bank acquired a new position in 10x Genomics in the 3rd quarter worth $64,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in 10x Genomics in the 4th quarter worth $66,000. Institutional investors own 79.16% of the company’s stock.

10x Genomics Company Profile

(Get Free Report

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

See Also

Analyst Recommendations for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.